CD274 and neoplasm: In the first-line setting, significant survival advantage over standard chemotherapy with anti-PD-1/anti-PD-L1(anti-PD-(L)1) monotherapy has been consistently observed in EGFR and ALK wild-type stage IV patients with tumor cell PD-L1 expression ≥ 50% [4,5].